Be Clinical
5 known investors
Be Clinical is a skincare brand that develops clinically informed formulations targeting causes of skin aging such as environmental stressors, biological changes, and lifestyle factors. Formerly known as Botnal, it combines botanical inspiration with dermatological research to deliver skincare products focused on measurable results.
Also known as Botnal
Founders & leadership
Investors · 5
Also in the syndicate · 4
Company profile
researched Aug 2026Be Clinical is a direct-to-consumer skincare brand based in India that develops products for ageing-related skin concerns such as fine lines and wrinkles, sagging, pigmentation and dull skin. Its catalogue includes face and body serums, creams and multi-product combination sets, among them PlumpX Serum (1.3% hyaluronic acid, anti-sagging), FirmX Serum (niacinamide and peptides), Revive 10 Eye Cream, Neck Repair Skin Tightening Night Cream, Blemish Balance Serum for menopausal skin, SmoothX Hand Cream, Lip Reset Balm, RootX Scalp Serum and SculptX Body Cream, with separate men's variants of several products. As of the source listing, 18 products were offered, priced between roughly ₹999 and ₹4,497 for bundles.
The company positions ageing as a biological process to be addressed with evidence-based formulation rather than cosmetic concealment. It states that its products are dermatologically tested and that its clinical trials are registered with the Clinical Trial Registry of India, with outcomes assessed using 3D imaging, firmness measurement tools and clinical evaluation. Formulations use advanced peptides, multi-molecular-weight hyaluronic acid, Hydroxypropyl Tetrahydropyrantriol, post-biotic ferments, retinol with Glaucine Complex, Pullulan, Haloxyl and Acetyl Hexapeptide-8, and acid blends of salicylic acid, LHA and glycolic acid. Products are described as fragrance-free, gender-neutral, suitable for sensitive and acne-prone skin, and intended to complement in-clinic professional treatments.
Be Clinical has moved formulation and manufacturing operations in-house to gain greater control over ingredients, production and quality, operating what its lead investor describes as a full-stack model spanning in-house R&D, manufacturing and clinically tested formulations.
Founding story
Be Clinical was founded by Hemangi Dhir and launched in May 2025; the founder has said the brand began selling products on 13 May 2025.
Business model
Direct-to-consumer sales of branded skincare products, sold through the company's own e-commerce website and also listed on the Flipkart marketplace. Formulation and manufacturing are handled in-house rather than outsourced, which increases fixed costs and capital requirements but gives the company control over ingredients and quality and can protect gross margins.
Product sales of individual serums, creams and balms (approximately ₹999–₹1,599 per unit) and discounted multi-product bundles (approximately ₹2,399–₹4,497), sold online with promotional discounts of up to 15% and pre-orders for new launches.
Traction
The company reports approximately 120,000 orders fulfilled since its May 2025 launch. Its website displays 769 customer reviews, with an earlier page citing over 580 verified reviews, and lists 18 products.
Latest developments
In August 2026 Be Clinical announced a ₹21 crore (about $2.2 million) seed extension round led by Sauce with participation from existing investor V3 Ventures and angel investors. Proceeds are earmarked for R&D, expanded manufacturing capacity, broadening the skin, body and haircare range, clinical testing, hiring and entry into new markets. The company has also brought formulation and manufacturing in-house and is taking pre-orders for a body treatment containing 10% urea, 1% V3DS Sculpt and 1% Morpholyss.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Operates in the Indian beauty and personal care market, which IMARC Group valued at $31.19 billion in 2025 and forecasts to reach $48.72 billion by 2034 at a 5.08% CAGR between 2026 and 2034. The category is crowded with established and newly funded brands; Be Clinical seeks to differentiate on clinical efficacy and longevity-oriented skincare.
Positions itself on evidence-led claims — clinical trials registered with the Clinical Trial Registry of India, instrumented outcome measurement, and fragrance-free, gender-neutral formulations — combined with a full-stack model of in-house R&D and manufacturing. Its investor cites this evidence-led, full-stack approach and an underserved market demographic as the key differentiators.
Technology
Formulation-led product development supported by clinical studies registered with the Clinical Trial Registry of India and measured via 3D imaging, firmness instrumentation and clinical evaluation. Technical elements cited include multi-molecular-weight hyaluronic acid combined with Hydroxypropyl Tetrahydropyrantriol for deeper penetration, a post-biotic ferment intended to stimulate endogenous hyaluronic acid synthesis, advanced peptides, retinol with Glaucine Complex, Pullulan, Haloxyl, Acetyl Hexapeptide-8, and a body formulation containing 10% urea, 1% V3DS Sculpt and 1% Morpholyss with a built-in gua sha applicator.
Go-to-market
Online direct-to-consumer selling via its own website, supplemented by marketplace distribution on Flipkart. Merchandising uses concern-based navigation (fine lines, sagging, pigmentation, dull skin), bundled combination sets, discounting, pre-orders and published customer reviews. Products are positioned as complementary to professional in-clinic treatments.
Consumers with ageing-related skin concerns — fine lines and wrinkles, sagging and loss of firmness, pigmentation, dull skin, dark circles, volume loss and hormonal or menopausal skin changes. Formulations are described as gender-neutral with dedicated men's variants of PlumpX, FirmX and RootX, are designed for Indian consumers, and are positioned for all skin types including sensitive and acne-prone skin.
Geography
India-focused, with pricing in Indian rupees and formulations stated to be designed for Indian consumers; the company has said it intends to enter new markets with its latest funding.
History
The brand launched in May 2025 and raised ₹2 crore that same month in a round led by Titan Capital. A ₹6 crore seed round led by V3 Ventures with participation from Titan Capital was announced in January 2026. In August 2026 the company announced a ₹21 crore (about $2.2 million) seed extension led by Sauce, by which point it reported roughly 120,000 fulfilled orders and had brought formulation and manufacturing in-house.
Risks & controversies
Commentary on the seed extension notes that in-house manufacturing raises fixed costs and adds factory management and compliance obligations relative to outsourced production, and that the company remains dependent on future funding, with cash burn, demand in new regions, quality consistency at scale and competition from other well-funded brands identified as key monitorables.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 5
launches, deals, and filingsD2C skincare brand Be Clinical raised Rs 21 crore (about $2.2 million) in a seed extension round led by consumer-focused VC firm Sauce, with existing investor V3 Ventures and angel investors including Mokobara founders Sangeet Agrawal and Navin Parwal, Reckitt executive Arjun Purkayastha and Shaunak Chirayu Amin. Funds are for R&D, manufacturing capacity, product range expansion across skin, body and haircare, clinical testing, hiring and new markets.
$2.2M source ↗
The company brought formulation and manufacturing operations in-house to gain greater control over ingredients, production and quality.
Seed round announced in January 2026, led by V3 Ventures with participation from Titan Capital.
Founder Hemangi Dhir said the brand began selling products on 13 May 2025.
Initial round of Rs 2 crore raised in May 2025, led by Titan Capital with participation from P-TAL founder Aditya Agarwal.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Be Clinicalbe-clinical.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Be Clinical do?
- Indian D2C skincare brand selling clinically tested anti-ageing serums and creams for skin, body and hair.
- Who founded Be Clinical?
- Be Clinical was founded by Hemangi Dhir.
- Who are Be Clinical's investors?
- Be Clinical's investors include V3 Ventures.